Raymond James & Associates Sells 16,788 Shares of SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH)

Raymond James & Associates lessened its holdings in SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH) by 26.0% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 47,766 shares of the company’s stock after selling 16,788 shares during the period. Raymond James & Associates owned approximately 0.81% of SPDR S&P Pharmaceuticals ETF worth $1,986,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the stock. Moors & Cabot Inc. raised its position in SPDR S&P Pharmaceuticals ETF by 18.4% in the first quarter. Moors & Cabot Inc. now owns 6,920 shares of the company’s stock worth $283,000 after purchasing an additional 1,076 shares in the last quarter. Cavalier Investments LLC bought a new stake in SPDR S&P Pharmaceuticals ETF during the first quarter worth about $2,300,000. Advisors Preferred LLC bought a new stake in SPDR S&P Pharmaceuticals ETF during the first quarter worth about $46,000. Wharton Business Group LLC grew its stake in SPDR S&P Pharmaceuticals ETF by 3.6% during the first quarter. Wharton Business Group LLC now owns 104,880 shares of the company’s stock worth $4,361,000 after buying an additional 3,655 shares during the last quarter. Finally, Oliver Luxxe Assets LLC grew its stake in SPDR S&P Pharmaceuticals ETF by 5.0% during the first quarter. Oliver Luxxe Assets LLC now owns 6,419 shares of the company’s stock worth $267,000 after buying an additional 306 shares during the last quarter.

XPH opened at $37.70 on Thursday. SPDR S&P Pharmaceuticals ETF has a one year low of $34.51 and a one year high of $49.97.

COPYRIGHT VIOLATION NOTICE: “Raymond James & Associates Sells 16,788 Shares of SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH)” was reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2019/06/13/raymond-james-associates-sells-16788-shares-of-spdr-sp-pharmaceuticals-etf-nysearcaxph.html.

SPDR S&P Pharmaceuticals ETF Company Profile

SPDR S&P Pharmaceuticals ETF (the Fund) seeks to replicate as closely as possible the total return performance of the S&P Pharmaceuticals Select Industry Index. The S&P Pharmaceuticals Select Industry Index represents the pharmaceuticals sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Read More: How is inflation measured?

Want to see what other hedge funds are holding XPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH).

Institutional Ownership by Quarter for SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH)

Receive News & Ratings for SPDR S&P Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply